Score Breakdown
Offering Ability
40
Cash Runway
85
Float Risk
0
Warrant Exposure
40
Convertible Debt
15
Dilution Forecast
⛈️
Warning
High probability of dilution event
model est. 45%
🔄 Reverse Split
model est. 70%
• 50-day avg $0.06 below $1 exchange minimum
• Only 4 months cash — financial pressure
💰 Capital Raise
model 35%
• Low cash runway: 4 months remaining
Market Data
Market Cap$27.32M
Shares Outstanding420.28M
Float387.95M
Cash$1.16M
Debt$500.0K
Short InterestN/A
Institutional Holdings
QoQ: ↓ 5.0% shares (2026Q1 vs prior)
6 institutional holders · 202.4K shares
#1
HOME FEDERAL BANK OF TENNESSEE
100.0K shares
#2
Wealth Preservation Advisors, LLC
52.6K shares
#3
ACADEMY CAPITAL MANAGEMENT
20.0K shares
+ 3 more holders Sign up free to view →
Institutional holder totals are aggregated from ownership filings and may use a different share basis or reporting date than public float. They are not a reconciliation against tradeable float.
Short Interest
Short Interest801.8K
Days to Cover2.1
% of Float0.2%
FINRA data as of Jul 31, 2026
Recent SEC Activity
xbrl
XBRL CONVERTIBLE
2025-12-31
Full SEC filing analysis available with free account →
Recent News
No recent news
Factual PVCT Dilution Snapshot
Provectus Biopharmaceuticals, Inc. (PVCT) has a DilutionScore of 50/100, rated Medium dilution risk. Score date: August 28, 2026.
- Recent SEC activity tracked for PVCT: xbrl on 2025-12-31.
This automatically generated snapshot is assembled from stored DilutionWatch data fields and may contain data-source errors or omissions. It is not financial advice, not investment research, and not a recommendation. Do your own research and review the full disclaimer and terms of service.
Related Stocks — MEDIUM Risk
Other MEDIUM dilution risk stocks tracked by DilutionWatch with similar profiles: